News & Updates

Radiographic progression minimal even after long-term bimekizumab use in r-axSpA patients

Two years of treatment with the monoclonal IgG1 antibody bimekizumab led to minimal spinal radiographic progression in patients with radiographic axial spondyloarthritis (r-axSpA) in the open-label extension (OLE) of the phase III BE MOBILE 2 study.

Delayed vs early response to ustekinumab, adalimumab shows similar outcomes in CD

Patients with moderate-to-severe Crohn’s disease (CD) with delayed response to adalimumab or ustekinumab display similar 1-year clinical outcomes to those with an early response, reports a study.

Retrospective study validates nirsevimab role against RSV in infants

A retrospective cohort study evaluating participants from Catalonia, Spain reinforces the potential of immunoprophylaxis with the novel monoclonal antibody nirsevimab in combating respiratory syncytial virus (RSV)-related outcomes in infants in the hospital and primary care settings.

Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

In COVID-19 patients, antibiotic therapy should be reserved only for suspected bacterial superinfections.

However, international data from over 1 million hospitalized COVID-19 patients across 65 countries showed that antibiotics were commonly prescribed empirically despite the low rates of reported bacterial co-infection.¹

Novel cardiac myosin inhibitor helps with exercise capacity in obstructive HCM

Treatment with the oral selective cardiac myosin inhibitor aficamten produced improvements in peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), as shown in the phase III SEQUOIA-HCM trial.